Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. TGFβ isoform mRNA expression and pathway activation in individual tumors.
  • Fig. S2. Characterization of recombinant latent TGFβ1 complexes.
  • Fig. S3. SRK-181 does not bind active TGFβ growth factors.
  • Fig. S4. Characterization of LLC-presenting molecule expression in LN229 cells.
  • Fig. S5. SRK-181 inhibits activation of mouse latent TGFβ1 LLC.
  • Fig. S6. Activation of peripheral human Treg cells induces GARP and TGFβ1 LAP expression on their cell surface.
  • Fig. S7. SRK-181 Fab binding protects three regions on TGFβ1 SLC from hydrogen/deuterium exchange.
  • Fig. S8. SRK-181 and integrin αVβ6 can bind to TGFβ1 SLC simultaneously, suggesting an allosteric mechanism of inhibition.
  • Fig. S9. Selection of syngeneic mouse tumor models that recapitulate profiles from CBT-resistant human tumors.
  • Fig. S10. Induction of prolonged tumor control with SRK-181-mIgG1/anti–PD-1 combination treatment in multiple tumor models.
  • Fig. S11. Further characterization of the treatment effect of SRK-181/anti–PD-1 in MBT-2 tumors.
  • Table S1. Percent amino acid sequence identity across human TGFβ isoforms.
  • Table S2. Animals euthanized early due to health reasons or found dead.
  • Table S3. qPCR reagent list.
  • References (6270)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (.pdf format). Nonclinical toxicology study summary.
  • Data file S2 (Microsoft Excel format). Original data.